BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38294686)

  • 1. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
    Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
    Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
    Front Oncol; 2022; 12():922127. PubMed ID: 35912272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
    Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
    Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
    Cai M; Zhu J; Zhou G
    Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.
    Zhang RS; Liu J; Deng YT; Wu X; Jiang Y
    Cancer Med; 2022 Jun; 11(11):2271-2283. PubMed ID: 35191609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
    Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
    Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
    [No Abstract]   [Full Text] [Related]  

  • 8. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
    Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
    EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
    Zhang XY; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial.
    Li T; Dong Y; Wei Y; Wang S; Liu Y; Chen J; Xiong W; Lin N; Huang X; Liu M; Yan X; Ye Z; Li B
    Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38483309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
    Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
    Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
    Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
    Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma].
    Guo X; Zhuang RY; Zhou YH; You CL; Zhang Y; Feng F; Shen ZM; Wang WS; Liu Y; Zhang HX; Tong WQ; Lu RK; Luo R
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2428-2434. PubMed ID: 36000371
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
    Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
    JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
    Wang ZM; Zhuang RY; Guo X; Zhang CL; You Y; Chen LS; Liu WS; Zhang Y; Luo RK; Hou YY; Lu WQ; Zhou YH
    Clin Cancer Res; 2022 Dec; 28(24):5290-5296. PubMed ID: 36228149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
    Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
    Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
    Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
    Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.